Trial | NCT01836757  Report issue

Title

Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage
The Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Joint Cartilage Associated With the Degeneration of the Chondrocyte

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    100
To delineate the effect of MSM on osteoarthritis
Objective: To delineate the effect of MSM on osteoarthritis of large joints. Design: Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA to be divided in 2 groups. Intervention is either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured are the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician assessments and SF-36 (overall health-related quality of life).
Study Started
Sep 30
2012
Primary Completion
Sep 30
2013
Anticipated
Study Completion
Oct 31
2013
Anticipated
Last Update
Apr 22
2013
Estimate

Drug MethylSulfonylMethane (MSM)

Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)

Drug Placebo

MSM group Experimental

Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)

Placebo Group Placebo Comparator

Placebo 3 gr twice a day for 26 weeks (6 gr/day total)

Criteria 

Inclusion Criteria:

Knee and hip OA
men and women >45 years of age

Exclusion Criteria:

any other type of arthritis
chronic pain syndrome
arthroscopic surgery in the past 8 months
intra-articular corticosteroidsin the past 8 months
hyaluronic acid injections in the past 8 months
narcotic pain killers use
renal or hepatic disease
body mass index (BMI) >45 kg/m2
cancer
No Results Posted